Older AML patients do not tolerate aggressive treatments as well as younger patients and tend to have more resistant clonal variants of the disease making it difficult to achieve a cure [4]. The potential for development of splice variant specific targeting therapies may help reduce treatment ...
Bexmarilimab shows encouraging results when combined with standard of care treatments for patients with acute myeloid leukemia and myelodysplastic syndromes. Read More Activity Shown With Revumenib in KMT2Ar AML/ALL Leads to Early Trial Completion Jordyn Sava October 4th 2023 Based on the recommend...
There are no studies analyzing how therapeutic changes impact on outcomes of older AML patients. This study analyzes patient´s and disease characteristics, treatment patterns, and outcomes of 3637 AML patients aged ≥60 years reported to the PETHEMA r
Patients age >65 constitute a large proportion of new diagnoses and continue to have poor outcomes, with one-year survival rates of approximately 28% in those without favorable risk disease [2], Current treatments for older patients Include anthracy-cline-based induction chemotherapy (IC) followed...
The difficulty is identifying those patients who are likely to benefit from intensive treatments at the time of diagnosis. Treatment recommendations for older adults with this disease range widely and are often based to a larger extent on chronologic age. Research focused on identifying those older ...
Melissa L. Larson, MD, discusses available treatments for patients with acute myeloid leukemia, as well as others that are in the pipeline.
The PLK1 inhibitor volasertib acquired Food and Drug Administration breakthrough therapy status in 2013 for AML. A recent phase 2 clinical trial was conducted in older AML patients ineligible for remission induction therapy, evaluating their response to low-dose cytarabine with or without volasertib.46...
which was the pivotal trial for gilteritinib, and they're doing very well. Gilteritinib is a "less difficult drug" for patients because it has fewer side effects and works much better than high-intensity chemotherapy in older patients. Gilteritinib allows patients to have a much better qu...
Additionally, more than half of AML patients at diagnosis are older than 65 years, and frequently have antecedent hematologic disorders, adverse cytogenetic abnormalities, and other clinically significant comorbid conditions3. Consequently, aged patients often have poor tolerance to cytotoxic drugs with ...
been also recommended as temporary alternative to intensive CHT in older fitNPM1-mutated AML patients during COVID-19 pandemic [54,55]. MRD assessment may be particularly helpful under these circumstances, although the optimal time points for monitoring need to be established for this combo [56]...